This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

UK-India FTA is a missed opportunity for IP protection, AstraZeneca exec says

By Douglas Clarke-Williams ( December 2, 2025, 16:49 GMT | Insight) -- AstraZeneca executive Mike Archer said on Tuesday that the UK-India Free Trade Agreement has failed to address recognized issues with India’s stance towards third-country IP, stymying hopes that the FTA would open the Indian market to brand-name UK pharmaceuticals.A representative of AstraZeneca told UK lawmakers on Tuesday that the Free Trade Agreement between the UK and India had failed to address several barriers to the import of patented medicines into India, missing the chance to grow the current level of UK pharma exports to that country....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections